24 May 2024
24 May 2024
Shares in the pharma company rose 40% in pre-market trading.
Research indicates that designing clinical trials with the patient in mind reduces recruitment times and enhances trial performance. Daniel J. Herron, a life sciences specialist, explains why one of the key factors in improving participant involvement is document readability.
Shares in Merus rose by 15% in premarket trading, following the announcement of positive Phase II data to be presented at ASCO.
In the ONWARDS 6 trial, insulin icodec demonstrated a significantly higher rate of hypoglycaemic episodes.
The cost saving programme is expected to save the company approximately $1.5bn by 2027.
The approval is based on robust clinical evidence, including findings from a global Phase III clinical trial.
After analysing data from a recent Phase III trial, Otsuka terminated its clinical programme for AVP-786.
Boehringer and OSE have also expanded two solid tumour programmes into cardiovascular-renal-metabolic (CRM) indications.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
